Compass Pathways CEO Kabir Nath said the company plans to “go slow before we go fast” as it approaches regulatory submission and prepares for a potential psychedelics approval environment in the US. Nath warned that early patient or provider experiences could influence broader adoption across the sector. For developers and investors, the message underscores that the commercial phase of psychedelics may hinge as much on post-approval execution—training, patient support pathways, and safety monitoring—as it does on the clinical package.